Sign In
Buy SILO
$4.19
-0.0600 (-1.41%)
At Close: Jul 31, 2026
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
08:13am, Wednesday, 07'th Aug 2024
Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company�
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
08:20am, Friday, 26'th Jul 2024
Presentation to feature Silo's novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmenta
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
04:45pm, Monday, 22'nd Jul 2024
SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulat
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:01am, Friday, 19'th Jul 2024
SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulat
Why Is Silo Pharma (SILO) Stock Up 60% Today?
02:25pm, Thursday, 18'th Jul 2024
Developmental-stage pharmaceutical firm Silo Pharma (NASDAQ: SILO ) — which specializes in both traditional and psychedelic therapeutics to address stress-induced psychiatric disorders — saw its s
Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug
12:44pm, Thursday, 18'th Jul 2024
Silo Pharma Inc SILO stock is surging on Thursday, with a session volume of 88 million compared to an average volume of 3.2 million, as per data from Benzinga Pro.
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
08:25am, Thursday, 18'th Jul 2024
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to support IND-enabling studies SARASOTA, FL, July 18, 2024 (G
Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?
10:50am, Tuesday, 16'th Jul 2024
Silo Pharma Inc SILO shares are trading higher on Tuesday on a high session volume of over 87 million.
Why Is Silo Pharma (SILO) Stock Up 123% Today?
08:00am, Tuesday, 16'th Jul 2024
Silo Pharma (NASDAQ: SILO ) stock is rocketing higher on Tuesday after the developmental stage biopharmaceutical company secured a new global license. This license covers the development, manufacturi
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
06:30am, Tuesday, 16'th Jul 2024
Agreement enhances Company's intellectual property portfolio SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage b
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
08:50am, Wednesday, 26'th Jun 2024
Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards first-in-human trial SARASOTA, FL, June 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasd
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
08:18am, Friday, 07'th Jun 2024
Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developm
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
04:50pm, Thursday, 06'th Jun 2024
SARASOTA, FL, June 06, 2024 (GLOBE NEWSWIRE) -- SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutic
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
08:41am, Tuesday, 04'th Jun 2024
Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a deve
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
08:45am, Tuesday, 21'st May 2024
The study has identified a potentially new drug formulation that could potentially extend the period of remission and prevent relapse in patients with depression.
